Outset Medical's (OM) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Outset Medical's stock rating has been reiterated as a "sell (D-)" by Weiss Ratings, indicating a lack of confidence among analysts.
• Despite the negative rating from Weiss, the stock received varying opinions from other analysts, with a consensus target price of $24.67 and an average rating of "Moderate Buy."
• Outset Medical's stock price has appreciated by 5.3%, and the company has a market capitalization of approximately $280.94 million.

Outset Medical (NASDAQ:OM - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other analysts have also recently weighed in on the company. BTIG Research set a $37.00 price objective on Outset Medical and gave the company a "buy" rating in a research report on Monday, July 14th. Royal Bank Of Canada restated a "sector perform" rating and issued a $22.00 price objective on shares of Outset Medical in a report on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $24.67.

Outset Medical Stock Up 5.3%

NASDAQ OM opened at $15.81 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 7.47 and a quick ratio of 6.05. The stock has a market capitalization of $280.94 million, a PE ratio of -0.78 and a beta of 2.13. Outset Medical has a 1 year low of $5.85 and a 1 year high of $25.35. The business's 50-day moving average is $14.03 and its 200 day moving average is $15.35.

Institutional Investors Weigh In On Outset Medical

A number of hedge funds have recently modified their holdings of the business. Woodline Partners LP purchased a new stake in shares of Outset Medical in the 1st quarter worth $14,663,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Outset Medical in the 1st quarter worth $2,556,000. TD Asset Management Inc purchased a new stake in shares of Outset Medical in the 1st quarter worth $589,000. Alyeska Investment Group L.P. purchased a new stake in shares of Outset Medical in the 1st quarter worth $18,836,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of Outset Medical in the 1st quarter worth $9,293,000.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.